Highlighting Progress in Fight Against Parkinson’s Disease with Conversations’ New Look

Highlighting Progress in Fight Against Parkinson’s Disease with Conversations’ New Look

03.27.14 | By

This week’s Medicines in Development report for Parkinson’s disease examines the work currently underway to help the 1.5 million Americans who are affected by the progressive neurological condition. While high-profile Parkinson’s patients like Michael J. Fox and Muhammed Ali are well-known, the vast majority of the 60,000 people who develop Parkinson’s every year fight the disease in obscurity. Fortunately, there are 37 new medicines to combat Parkinson’s disease in the biopharmaceutical pipeline, with additional research conducted daily.

The release of our Medicines in Development report is a good opportunity to take a step back and assess what is being done to combat some of the most pressing challenges facing patients, providers and researchers.

With that in mind, we asked our Conversations contributors the following:

What is the greatest issue facing Parkinson’s patients today, and what can be done to accelerate the research and development of new therapies to help them?

Additionally, we’re excited to showcase our redesigned Conversations platform.

When we launched Conversations last June our objective was to bring discussions out from behind closed doors to facilitate an open, collaborative dialogue about some of the most pressing issues in health care today. Thus far, Conversations has featured 27 questions and more than 120 responses ranging from diabetes to the impact technology is having on innovation and medicine.

Conversations brings in the best and brightest minds to lend their unique ideas and perspectives and has thus far brought multi-stakeholder engagement throughout the health care community. The platform will continue to explore important topics such as access to affordable medicines, the importance of quality and the meaning of value, but its evolution will provide an even better user experience that facilitates thought-provoking questions and dynamic dialogue among participants.

I encourage you to check out the new Conversations forum here, and let us know what you think, and respond to this week’s question. We’re always on the lookout for ways to make it easier to access content and weigh in with comments, so please continue to share them directly in the forum or on Twitter or Facebook


Hide Comments

More On PhRMA — powered by PhRMApedia


Cost in Context